Ms. Zhou, who is 41 years old, went through surgery and chemotherapy for breast cancer 4 years ago and took triamcinolone for nearly 4 years orally, and her condition was very well controlled with regular recheck. Suddenly one day, she came to my clinic, “Director Wang, I heard that triamcinolone is not just for 5 years, but now it takes 10 years, is that right?” “Yes!” ”10 years!? Another 5 years to worry about, will long-term medication be bad for your health ……” Ms. Zhou threw out a series of questions. Since the ASCO guidelines for the endocrine treatment of breast cancer were updated in May 2014 to “extend the duration of adjuvant endocrine therapy for hormone receptor-positive breast cancer to 10 years,” the majority of patients have reacted like Ms. Zhou whenever I instructed them to endocrine breast cancer for 10 years. Breast cancer is a disease related to estrogen level, and high estrogen level is a risk factor for breast cancer recurrence, and endocrine therapy is to block the effect of estrogen or inhibit estrogen production to prevent breast cancer recurrence, and endocrine therapy is an integral part of comprehensive breast cancer treatment. However, most breast cancer patients have very limited knowledge of endocrine therapy and even feel that it is a burden and avoid endocrine therapy. With the progress of breast cancer clinical trials, new research data began to guide new clinical decisions. According to the latest 2014 ASCO guidelines, the 5-year standard endocrine drug treatment duration for patients with stage I-III hormone receptor-positive breast cancer has been revised, and the recommended duration of endocrine therapy is as follows: 1. 5 years of triamcinolone therapy for premenopausal patients; after 5 years of triamcinolone, follow-up endocrine therapy is given according to menstrual status If premenopausal patients are still premenopausal, they should continue to take triamcinolone for 5 years, for a total of 10 years; if menopause is determined after 5 years of triamcinolone, they can continue to take oral triamcinolone for 10 years, or they can switch to aromatase inhibitors and continue to take them for 5 years, for a total of 10 years of triamcinolone and aromatase inhibitors. 2. Menopausal patients can be given triamcinolone for 10 years; or aromatase inhibitors for 5 years; or first triamcinolone for 5 years, then switch to aromatase inhibitors for 5 years, accumulating 10 years of endocrine therapy. The extension of endocrine therapy to 10 years improves overall survival of hormone receptor positive patients and reduces breast cancer mortality, risk of recurrence, and incidence of contralateral breast cancer; of course the adverse effects of endocrine therapy are the risk of osteoporosis, etc. Aromatase inhibitors are superior to triamcinolone in terms of endometrial cancer, stroke, and thromboembolic events. However, overall, the benefits of prolonging the duration of endocrine therapy for hormone receptor-positive breast cancer patients far outweigh the disadvantages. Therefore, the best endocrine therapy for 41-year-old Ms. Zhou is to continue oral triamcinolone acetonide for a full 10 years. As doctors, we should let our patients know that endocrine therapy is an opportunity, not a burden.